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ABSTRACT 
Hope C. Davis: Associations Between Biochemical Markers of Cartilage Metabolism 
and Gait Biomechanics in Healthy Participants 
(Under the direction of Anthony C. Hackney) 
 
 
Introduction: Mechanical loading is associated with cartilage breakdown in people 
with knee osteoarthritis (KOA); it is unknown if this association exists in healthy young 
individuals. Purpose: Determine associations between biomarkers of collagen turnover 
(synthesis:breakdown) and peak vertical ground reaction force (vGRF) in healthy young 
individuals.  Methods: Resting serum samples and walking gait kinetics were collected 
from 24 healthy, young individuals.  Type II collagen synthesis (Collagen type II C-
propeptide; CPII) and breakdown (Collagen type II cleavage product; C2C) were 
examined via enzyme-linked immunosorbent assays (ELISA). Gait kinetics were 
assessed during walking trials. Pearson product (r) moment correlations were used to 
determine associations between transformed (base-10 log scale) collagen turnover and 
peak vGRF. Results: 24 subjects (age=20±2 years, BMI=23.4±3.0) completed this 
study. There was a moderate association between CPII:C2C ratios and peak vGRF 
approaching significance (r= 0.363, p=0.081). Discussion: Higher loading in gait may 
increase collagen synthesis-to-degradation ratio in healthy young subjects. 
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CHAPTER 1 
 
Introduction 
Over the past several decades, musculoskeletal injuries have become an 
increasing concern in the general population. (Bjorklund 1998).  Specifically, 
osteoarthritis (OA) is one of the most prevalent musculoskeletal diseases, and it will 
continue to rise with the increasing age of the population (Bjorklund 1998). In 2008, an 
estimated 27 million adults suffered from OA (Lawrence et al., 2008), and by 2020 it is 
predicted to be the fourth leading cause of disability (Bjorklund 1998).  About 80% of OA 
patients suffer from limited mobility (Guccione et al., 1994), and an estimated 25% 
cannot perform activities of daily living without assistance (Guccione et al., 1994).  
Furthermore, OA is a major healthcare cost in the United States, with total knee 
replacements (i.e. a common treatment for end stage OA) estimating over $28 billion 
dollars (Murphy et al., 2012).  Job-related OA costs are $3.4 to $13.2 billion per year; 
with adults suffering from KOA (KOA) reporting more than 13 lost workdays per year 
due to health (Buckwalkter et al., 2004).  KOA is so debilitating because the knee joint is 
a significant shock absorber for any type of walking, climbing, or load-bearing activity.   
KOA affects both young and older populations, although the risk factors 
associated for the populations can be different. Sports participation, injury to the joint, 
obesity, certain genetics, previous knee trauma, old age, female gender, obesity, 
repetitive use of joints, low bone density, muscle weakness, and joint laxity can lead to 
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KOA (Heidari, 2011). Also, individuals who exhibit aberrant biomechanics during gait 
may have a higher risk of developing KOA (Maly, 2008; Baliunas et al., 2002).  Knee 
adduction moment is one common variable assessed in KOA patients (Maly, 2008). 
High adduction moments have been associated with the disease (Maly, 2008). 
Currently, KOA is diagnosed after confirmation of radiographic damage within the joint. 
This damage is characterized by joint space narrowing due to osteophyte formation 
(Kijowski et al., 2006). Further bone sclerosis and subchondral cysts are used assess 
the severity of OA (Kijowski et al., 2006). By the time radiographic evidence is present, 
the patient already has irreversible cartilage breakdown and bone remodeling.  
Therefore, the development of early intervention techniques to will be essential in 
decreasing the physical and financial burden associated with OA. 
Current research assesses biochemical and biomechanical markers in OA 
patients in hopes of finding new methods of detection for high-risk populations. 
Clinically, OA is diagnosed once these irreversible changes in the bone and cartilage 
are radiographically present (Kijowski, 2006).  However, there is evidence that 
biochemical changes alter cellular metabolism at the knee prior to radiographic evident 
changes (Garnero et al., 2001). 
Local inflammation at the knee for any number of reasons can trigger a cascade 
of metabolic events leading to radiographic changes.  Cartilage, bone and synovium can 
all release cytokines and similar proinflammatory mediators (Berenbaum, 2013), which 
increase production of matrix metalloproteinases (MMP; Berenbaum, 2013). MMPs 
cleave type II collagen, the backbone of articular cartilage (Berenbaum, 2013); this 
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event can lead to cartilage damage, the cardinal characteristic of KOA.  Weight gain 
(metabolic syndrome), aging, and acute joint trauma such as anterior cruciate ligament 
(ACL) injury (Lohmander et al., 1994) can all trigger this local metabolic change. 
Proinflammatory cytokines can affect joint metabolism for years after the initial injury 
(Lohmander et al., 1994). This metabolic alteration can lead to cartilage, bone, and 
synovium breakdown, all increasing the risk of KOA. 
Although biochemical changes potentially begin the cascade of events leading to 
OA, biomechanical changes can progress OA and increase the severity of it. Several 
decades ago studies examined cartilage damage as a result of aberrant loading in 
animal models. Results showed that repetitive and aberrant loading in rabbits can lead 
to subchondral bone thickening and cartilage fibrillations (Farkas et al., 1987; Radin et 
al., 1984). In human studies evidence suggests that patients with KOA have altered 
peak vertical ground reaction forces (vGRF) compared to healthy subjects (Gyory et al., 
1976; Stauffer et al., 1977; Radin et al., 1991). Many studies currently focus on aberrant 
gait as not only a result but also a cause of KOA (Childs, 2003). Examining associations 
between biomechanics and biochemical markers could identify at risk patients before 
KOA symptoms begin. 
Researchers realize that both biochemical and biomechanical changes at the 
knee joint precede OA diagnosis; however, the association between the changes is not 
well understood.  It is hypothesized that an association between biochemical markers 
and biomechanical markers exists, even in healthy individuals with no symptoms of 
KOA.  
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Serum markers of collagen turnover and proteoglycan breakdown can be used to 
assess joint metabolism (Attur et al., 2013). Certain markers may indicate if an 
individual is more likely to develop KOA or if OA will further progress (Attur et al., 2013). 
Collagen type-II C-propeptide (CPII) detects collagen synthesis, while cartilage 
degradation is detected by serum concentrations of collagen type-II cleavage product 
(C2C; Cahue et al., 2007).  The ratio of CPII: C2C describes collagen turnover (Cahue 
et al., 2007). Additionally, proteoglycan, another structural macromolecule in cartilage, 
can be indicative of knee joint cellular metabolism (Larsson et al., 2012). Proteoglycan 
release into the synovial fluid may be associated with cartilage catabolism (Lohmander 
et al., 1999) and another sign of KOA progression.  Although there is not one 
biochemical marker that can diagnose or predict KOA, evaluating several different 
markers can help determine metabolic processes of the knee joint prior to radiographic 
changes. 
Although there is evidence that shows biochemical and biomechanical changes 
following joint trauma, there is little research done on serum biomarkers in a healthy 
population. Assessment of cartilage markers in asymptomatic subjects will add to the 
body of knowledge of OA biochemical markers found in serum and biomechanical 
markers.  
Purpose 
 The purpose of this study is to assess the association between collagen turnover 
(CPII: C2C) and mechanical loading (peak vGRF) in a healthy population.  
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Research Question 
1. Will there be an association between collagen turnover and peak vGRF? 
Research Hypotheses 
1. There will be a negative association between collagen turnover and peak vGRF.   
Definition of Terms 
Knee Osteoarthritis 
KOA is one of the most prevalent causes of disability in the United States 
(Lawrence et al., 2008). It is characterized first by articular cartilage breakdown, causing 
the femur and tibia to rub painfully against each other during weight bearing activities 
(Neogi & Zang, 2013). Subchondral bone thickening and general pain of the joint are 
also symptoms of the disease (Radin, 1984).  While the current study focuses on 
articular cartilage, recent literature suggests that changes to other surrounding tissues 
such as synovial fluid (Benito et al., 2005) and bone (Ishijima et al., 2011) may 
accompany or occur prior to cartilage breakdown.   Although there are many risk 
factors, two discussed in this thesis are altered cartilage metabolism (Berenbaum, 
2013) and aberrant gait (Stauffer et al., 1977). 
Cartilage Metabolism 
Cartilage metabolism is defined as the physiological events that take place at the 
cellular level in the articular cartilage of the knee. Articular cartilage contains one cell 
type, the chondrocyte (Poole et al., 2002). The chondrocyte is responsible for making 
type II collagen, the strong backbone of the articular cartilage. This cell also makes 
proteoglycan; a large protein structural macromolecule embedded in type II collagen 
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that contributes to the strength of cartilage (Poole et al., 2002). Both type II collagen and 
proteoglycan are regulated by synthesis and degradation; however, in a diseased joint 
the resulting ratio can decrease causing loss of articular cartilage, the hallmark 
characteristic of KOA (Lohmander et al., 1992). 
Gait Biomechanics 
 Gait biomechanics include alignment of the lower extremity as well as joint torque 
moments that occur during the different phases of human gait. Peak vertical ground 
reaction force (vGRF) is a commonly used parameter to assess gait mechanics (Childs 
et al., 2004). Although it is still unclear if aberrant mechanics is a cause of OA, several 
studies demonstrate that alterations in mechanical loading can cause cartilage 
fibrillations (Radin et al., 1973).   
Assumptions 
1. Participants will be honest in medical history questionnaire.   
2. All participants will have no history of ACL, meniscus or other knee injuries. 
3. Participants will not engage in unnecessary physical activity during the 24-hours 
prior to the two sessions. Participant will still be allowed to walk to and from 
class/work and complete activities of daily living. 
4. Serum measurements accurately predict synovial fluid metabolism 
measurements. 
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Delimitations 
1. Participants must be healthy males or females between the ages of 18 and 35. 
2. They must be physically active according to current physical activity guidelines 
(US Department of Health and Human Services, 2008). 
3. Participants will be excluded if they have history of orthopedic injury or surgery 
on either lower limb or any current fractures or activity restrictions in the past 6 
months. 
4. Participants will be excluded if they have osteoporosis, are post-menopausal, are 
undergoing hormone replacement therapy, have growth hormone or androgen 
deficiency, hypothyroidism, chronic renal failure, rheumatoid arthritis, or have a 
BMI over 30. 
5. Participants will be excluded if they have a current musculoskeletal condition 
limiting gait, a central nervous system disorder or balance issue, a need of an 
external device for walking, history of concussion, or a heart condition limiting 
exercise capacity. 
6. Participants will be excluded if they are on blood thinner medication, are 
pregnant, have a history of blood infection, or a self-reported fear of needles. 
Limitations 
1. Assumption must be made that serum markers are indicative of synovial fluid 
markers. 
2. This study is only generalizable to healthy individuals between the ages of 18 
and 35. 
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Significance of Study 
With present technology, KOA is diagnosed after irreversible changes in the joint 
have been made. A patient already suffers from pain and potentially limited mobility, 
which greatly decreases his or her quality of life. Markers of cartilage breakdown 
correlate with KOA severity and progression (Cahue et al., 2007). Additionally, it is 
known that aberrant mechanical loading can cause cartilage fibrillations (Radin et al., 
1973).  The findings from this research project could suggest that cartilage breakdown is 
associated with a higher loading in the joint in a healthy population. If this finding exists, 
future studies can focus on earlier detection and even prevention of KOA. Perhaps OA 
prevention programs could focus on lowering reaction forces placed on the knee joint 
during physical activities. Additionally, monitoring patients’ and athletes’ cartilage 
metabolism biomarkers could prevent KOA or at least OA progression.  Currently, KOA 
costs the United States millions of dollars each year in health care and missed 
workdays (Murphy et al., 2012; Buckwalter et al., 2004).  By far the most efficient way to 
lower these costs is to focus on early detection and prevention. By assessing 
biochemical alterations that occur before radiographic changes, joint disease prevention 
may become an actuality.  
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CHAPTER 2: LITERATURE REVIEW  
This review will examine properties of tibiofemoral joint tissue physiology and 
mechanical loading of articular cartilage, as well as alterations that can increase the risk 
of knee osteoarthritis (OA). Articular cartilage surrounds the femur and tibia that make 
up the tibiofemoral joint, providing a strong and protective layer between the bones. 
Articular cartilage is composed primarily of collagen, proteoglycans, and chondrocytes 
(Buckwalter et al., 2005). Chondrocytes are the only type of cell that resides in the 
cartilage, and they are responsible for all aspects of cartilage metabolism.  
Chondrocytes maintain the ratio of synthesis to degradation for all macromolecules in 
the cartilage (Buckwalter et al., 2005). Proinflammatory cytokines can increase both 
local and systemic inflammation, both of which alter the cartilage metabolism 
(Berenbaum, 2013). Biochemical markers in serum can indicate levels of 
macromolecule synthesis and degradation. Thus, this review will cover markers of 
collagen synthesis and degradation. In addition to cartilage metabolism, alterations in 
mechanical loading at the joint can increase the risk of onset and progression of KOA. 
Therefore, this review will also discuss peak vertical ground reaction force (vGRF) and 
its role as a marker of mechanical loading. Finally, it is hypothesized that biomechanical 
alterations can expedite biochemical changes via increased intracellular signaling. This 
process is known as mechanosignaling and will be briefly discussed. 
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Part I 
Articular Cartilage Composition 
The tibiofemoral joint is used in all weight-bearing activities, and therefore its 
structure is a critical shock absorber during walking, jumping, running, and other 
dynamic movements. A type of connective and force-absorbing tissue called articular 
hyaline cartilage surrounds the femur, tibia, and patella. This strong, hydrophilic 
structure allows for fluid joint motion.  
Articular cartilage is made up of structural macromolecules, chondrocytes, and 
water (Buckwalter et al., 2005). Compared to other tissues, cartilage has a low 
metabolic activity; however, interactions between different components contribute to 
maintaining cartilage health in the correct ratios (Buckwalter et al., 2005). The structural 
macromolecules collagen and proteoglycan weave together to form a strong and tensile 
material that is smooth and resistant to force (Buckwalter et al., 2005). Collagens make 
up the majority of the dry weight of cartilage, and although there are several different 
types, type II collagen is most prevalent (Buckwalter et al., 2005).  Proteoglycans are 
made of a protein core and at least one glycosaminoglycan chain, which contains at 
least one carboxylate or sulfate group (Buckwalter et al., 2005). These groups are 
negatively charged and repel similarly charged molecules while attracting cations. This 
property pulls water into the extracellular matrix, which gives articular cartilage the 
ability to compress and de-compress when loads are applied to the joint (Buckwalter et 
al., 2005). Articular cartilage contains both large aggregating and smaller 
nonaggregating proteoglycans; however, the large aggregating proteoglycans, known 
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as aggrecans, make up the majority of proteoglycan matter in cartilage (Buckwalter et 
al., 2005). These aggrecans link together to stay anchored within the matrix. This helps 
prevent deformation of the meshwork during mechanical loading.  
Proteoglycans and collagen, as well as several other types of smaller proteins, 
are coordinated in a highly ordered structure to form functioning articular cartilage. 
Chondrocytes, the only type of cell inside the articular cartilage, are responsible for 
regulating and maintaining structure.  Chondrocytes synthesize new collagen and 
proteoglycans, as well as breakdown dysfunctional cartilage (Buckwalter et al., 2005).  
Cartilage Metabolism 
Articular cartilage, especially in the knee joint, undergoes a wide range of 
stressors throughout a human’s lifetime. Mechanical loads can induce different amounts 
of stress and compressive strains based on the duration and type of mechanical loading 
occurring at the joint (Marasovic et al., 2009). Ability to resist these forces depends on 
maintaining a proper ratio of synthesis to degradation of macromolecules.  This turnover 
is a critical component of healthy cartilage metabolism. 
Chondrocytes are the sole cell found in articular cartilage, and they make up 
approximately 1% of cartilage’s total volume (Buckwalter et al., 2005), making 
maintenance a delicate process.   In healthy cartilage, turnover is very low, but it does 
still occur.   Chondrocytes release collagenases, small degradation enzymes that cleave 
mature collagen and proteoglycan at certain sites. New macromolecules replace the old 
ones, and structure is maintained. Matrix metalloproteinases (MMPs) are the main 
collagenases responsible for type-II collagen cleavage (Pelletier et al., 2008), while 
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MMPs and aggrecanases contribute to proteoglycan cleavage (Pollard et al., 2008).  
The cardinal characteristic of OA is loss of articular cartilage that surrounds the patella, 
femur and tibia (Poole et al., 2002).  One prevalent theory is that OA is initiated in part 
by a change in the cellular metabolism of articular cartilage, where synthesis of new 
molecules cannot keep up with an increase in degradation (Pollard et al., 2008).  
Increased cleavage of proteoglycans leads to increased levels of aggrecan fragments in 
surrounding synovial fluid and even serum (Pollard et al., 2008).  This enhanced 
cleavage can be the result of many mechanisms, including inflammation and joint 
trauma (Pollard et al., 2008).  The remaining aggrecan has room to expand and swell, 
causing stretching of the collagen framework (Pollard et al., 2008).  After this stretching, 
type II collagen is significantly more vulnerable to mechanical damage, and these 
combined effects can lead to increased cartilage breakdown due to decreased strength 
of the tissue (Pollard et al., 2008).  Additionally, chondrocytes become vulnerable to 
necrosis in this stage (Pollard et al., 2008). Chondrocyte death will lead to further 
disruption of the cellular matrix, and will eventually lead to an irreversible situation if not 
corrected early on (Pollard et al., 2008).   
Local Metabolic Factors 
Joint swelling is a common symptom of KOA, and it can be the result of local 
upregulation of proinflammatory mediators. One potential mechanism for local 
inflammation at the joint (known as synovitis) is release of inflammatory cytokines by 
cartilage, bone, and synovium (Berenbaum, 2013). These cytokines can increase 
expression of degradative enzymes via chondrocytes and ultimately increase cartilage 
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breakdown (Pollard et al., 2008).  After breakdown occurs, fragments are released into 
the joint where they make contact with the synovium. This invasion of foreign particles 
into the synovium can cause synovial cells to produce additional cytokines, starting an 
inflammatory feed forward loop that can be difficult to inhibit (Berenbaum, 2013).  This 
evidence suggests that local inflammation in the synovial tissue may be a driver in the 
OA process rather than a result of previous cartilage breakdown (Berenbaum, 2013).  
Innate immunity may also trigger local inflammation in the knee joint. Synovial fluid from 
patients with early cartilage damage show increased fibroblast-like synoviocyte 
responses to several receptor ligands of toll-like receptors (TLR; Nair et al., 2012). 
Binding of these ligands initiates intracellular signaling for inflammatory gene 
transcription (Nair et al., 2012). Additionally, increased levels of specific interleukin (IL-
15) proteins exist in early OA patients compared to late stage OA patients (Scanzello et 
al., 2009).  Although mechanisms are not well-established, the literature suggests that 
several different proinflammatory mediators facilitate the upregulation of degradative 
enzymes. 
Eventually, the shift of cartilage metabolism towards breakdown becomes 
irreversible and OA develops and progresses. Although not well established, increased 
MMP expression may play an important role in the eventual cartilage fibrillation 
(Tchetina, 2011).  Additionally, many cytokines not only increase degradation, but also 
inhibit synthesis processes important to maintaining cartilage turnover ratios (Sokolove 
et al., 2013).  Although the exact mechanism is undetermined, local metabolic 
alterations could be a key player in the onset and progression of KOA. 
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Systemic Metabolic Factors 
 While local metabolic alterations play an important part in early OA development, 
evidence also suggests that systemic cytokine activity can progress OA via cartilage 
breakdown (Berenbaum, 2013).  Inflammatory events that occur peripherally can 
influence cytokine upregulation inside of the knee joint tissue (Berenbaum, 2013).  
Several studies found increased levels of cytokines in OA patients’ serum compared to 
controls (Berenbaum, 2013).  One study showed that peripheral blood leukocytes (PBL) 
of OA patients with increased levels of IL-1B expression experienced a higher rating of 
pain and increased dysfunction (Attur et al., 2011), putting these patients at a greater 
risk of OA progression (Attur et al., 2011).  Likewise, leptin and adipokines, hormones 
with proinflammatory properties, have been studied in KOA. Leptin becomes biologically 
functional by binding to specific receptors that enhances the synthesis for MMP 
production (Gabay & Berenbaum, 2009).  Adiponectin acts similarly to leptin when it 
makes contact with articular cartilage. Adiponectin receptors are present on the surface 
of chondrocytes, and when bound facilitate an increase in additional cytokines as well 
as MMPs (Gabay & Berenbaum, 2008).  Other evidence shows an increased risk of 
hand OA in obese patients (Berenbaum, 2013).  While mechanical loading would not be 
an issue, systemic factors such as increased adipokines like leptin and adiponectin 
could play a role in increased risk of hand OA (Berenbaum, 2013).   
Local and systemic factors could both play an important role in KOA onset and 
progression. Although there are several hypotheses for exact mechanisms that bring 
about these changes, a large body of evidence suggests that local and systemic 
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alterations lead to the upregulation of MMPs via increased production by chondrocytes 
(Berenbaum, 2013; Gabay & Berenbaum, 2009; Tchetina, 2011).   
Biomarkers of Cartilage Metabolism 
Collagen Turnover 
Collagen turnover is defined as the ratio of collagen synthesis to degradation 
(Buckwalter et al., 2005). Collagen must be degraded as it ages in order to make room 
for new collagen. In a healthy, functional joint, there is both collagen degradation, as 
well as new collagen synthesis at a fairly constant ratio (Buckwalter et al., 2005).  MMPs 
are the main collagenases responsible for cleaving mature collagen. Once collagen is 
cleaved, it is considered waste and moved out of the articular cartilage (Poole et al., 
2002).  For several decades, studies have looked at varieties of cleaved collagen 
product in hopes of finding a biochemical marker that is an indicator of cartilage 
metabolism. Specifically, studies have focused on markers of collagen turnover 
(Garnero et al., 2002; Cahue et al., 2007).  Garnero et al. measured levels of cartilage 
synthesis and degradation markers individually and in ratio.  Results showed that the 
ratio of synthesis and degradation markers, or turnover, could predict OA progression in 
subjects better than individual markers (Garnero et al., 2002).  Cahue et al. employed 
similar methods and found an elevated ratio of degradation to synthesis (as reported by 
the author) that was associated with the likelihood of KOA progression between 
baseline and 18 months (Cahue et al., 2007).  Ishijima et al. found that while 
degradation markers alone remained unchanged in early OA patients, turnover 
decreased at the onset of OA (Ishijima et al., 2011).  Additionally, Cibere et al. found 
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that turnover measurements may be better at predicting differences between subgroups 
of OA patients. Individual markers of collagen synthesis and degradation were 
significantly different between radiographic OA patients and patients with no OA. 
However, when looking at collagen turnover, a difference was also discernable between 
pre-radiographic OA patients and patients without OA (Cibere et al., 2009). Examining 
turnover ratios could potentially be a method to find OA before it is radiographically 
evident (Cibere et al., 2009). 
Collagen Synthesis 
C-propeptide of type II procollagen (CPII) is a widely used serum biomarker to 
detect levels of cartilage synthesis (Nelson et al., 1998).  The precursor to newly formed 
collagen is known as procollagen. The two ends of procollagen are cleaved by 
collagenases as a final step in the production of type II collagen.  These fragments are 
detected in the CPII biomarker (Cahue et al., 2007).  Generally with increased collagen 
degradation, there is an accompanying increase in synthesis (Nelson et al., 1998). 
However, in pathological cartilage this new collagen is quickly cleaved, and the ratio of 
synthesis to degradation still decreases (Cibere et al., 2009; Cahue et al., 2007).  The 
decreased ratio is a reflection of arthritic conditions that favor degradation over 
synthesis (Cahue et al., 2007).  
Collagen Degradation 
Serum cartilage type II collagen cleavage product (C2C) is a common biomarker 
used to detect collagenase-mediated cleavage generated neoepitopes of type II 
collagen (Billinghurst et al., 1997; Cahue et al., 2007; Cibere et al., 2009; Ishijima et al., 
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2011; Poole et al., 2002).  MMPs 1, 8, and 13 are known to cleave mature type II 
collagen in both healthy and pathological collagen (Billinghurst et al., 1997).  Positive 
correlations were observed between C2C and transverse proton relaxation time of 
cartilage (King et al., 2004).   Alone, differences in C2C concentrations can be detected 
between OA and healthy patients (Cahue et al., 2007; Ishijima et al., 2011), but the ratio 
of synthesis to degradation provides a more sensitive measure and can distinguish 
between healthy and pre-radiographic OA participants (Cibere et al., 2009).   
Part II 
Mechanical Loading at the Knee 
 While there is evidence that metabolic alterations in joint tissue physiology 
increase the risk of cartilage breakdown, it is also known that aberrant mechanical 
loading contributes to OA onset and progression (Farkas et al., 1987; Radin et al., 1973; 
Radin et al., 1984).  Several decades ago studies examined the effects of impulsive 
loading on articular cartilage and subchondral bone in animal models. The aberrant 
loading led to cartilage fibrillations and subchondral bone thickening in the animal joints 
(Radin et al., 1984; Farkas et al., 1973).  Results showed that daily impulsive loading 
equivalent to the animals’ body weight led to knee joint changes consistent with what is 
seen in human knee joints (Radin et al., 1973). Repetitive impulsive loading produces 
more degenerative changes in articular cartilage than rubbing or other constant forms of 
loading (Radin, 1973). In another animal study, Torzilli et al. found that bovine cartilage 
explants appear to have a critical loading threshold before cell death and subsequent 
cartilage damage (Torzilli et al., 1999).  It is generally agreed upon that in humans, while 
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moderate loading is critical for joint health, overloading can lead to cartilage degradation 
(Sun, 2010).  Likewise, results from several studies indicate that mechanical 
overloading may stimulate signaling pathways of several proinflammatory cytokines and 
induce overexpression of MMPs (Sun, 2010).   Increased or aberrant mechanical 
loading could potentially alter joint tissue physiology, possibly leading to cartilage 
breakdown (Sun, 2010). However, most studies assessing associations between 
mechanical and physiological parameters focus on pathological populations.  Examining 
a healthy population is a necessary step to gain insight on how these parameters 
influence one another.  
Biomarkers of Mechanical Loading 
 Although many biomarkers of mechanical loading exist in the literature, one of 
the most robust and basic markers is peak vertical ground reaction force (vGRF). vGRF 
is the vertical component of force exerted by the subject while in contact with the ground 
(Marasovic et al., 2009).  In healthy gait, vGRF exhibits an M shaped curve as a result 
of the initial heel strike and final toe off (Marasovic et al., 2009).  One risk factor of KOA 
is overloading of the joints (Radin et al., 1973), and many injury prevention programs 
focus on decreasing vGRF during walking, running, and jumping (Padua & DiStefano, 
2009).  Although it is known that vGRF is altered after onset of KOA, there is little in the 
literature of associations in vGRF and cartilage metabolism in healthy populations.  
Mechanosignaling 
 Controversy over the initiation of OA from mechanics versus cartilage 
metabolism currently exists. However, recent discoveries on mechanosignaling may end 
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the debate in the future. Any aberrant mechanical stress applied to a joint can initiate 
intracellular signaling at the site of loading. Eventually this signaling could lead to 
overexpression of inflammatory mediators in the synovium (Berenbaum, 2013). By 
examining associations between mechanical loading and biochemical measurements, 
great progress could be made in early detection of OA. Examining associations between 
biomechanical and biochemical markers in a healthy population will contribute to the 
growing body of knowledge currently available on this topic. 
Summary 
 In summary, initiation of KOA is most likely a multifactorial cause. Literature 
suggests that alterations in cartilage metabolism that favor breakdown can result in 
increased likelihood of onset and progression of OA. Likewise, evidence shows 
increased risk of OA in patients with aberrant gait and mechanical loading. Previous 
research shows associations between biochemical and biomechanical factors in 
pathological subjects; however, no studies have examined this association in healthy 
subjects. Hence there is a scientific and clinical need for the proposed research study. 
Examining associations in healthy subjects will contribute to methods of early detection 
and prevention of KOA.    
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CHAPTER 3: METHODOLOGY 
Participants 
Thirty healthy, moderately active people from the University community between 
the ages of 18-35 will be recruited for this study. To achieve a power of 0.80 with α< 
0.05, an estimated 26 subjects will be required to detect significance (r=0.50; Lachin, 
1981).  Participants will sign a consent form (Appendix 1) after being thoroughly 
informed of the experimental protocol and any risks or rewards related to the study.  
Participants will be excluded from the study if they do not meet all of the criteria listed in 
the delimitations found in Chapter 1. Participants will agree over email to abstain from 
any unnecessary physical activity (i.e. anything other than walking to class or doing 
activities of daily living) 24 hours prior to the session. 
Instrumentation 
 Gait analysis will be conducted using two Bertec force plates (40x60cm, 
FP406010, Bertec Corporation, Columbus, Ohio, United States) as well as two sets of 
timing gates (TF100, Trac Tronix, Lenexa, Kansas, United States).  Height will be 
determined using a portable stadiometer (Perspectives Enterprises, Portage, MI USA), 
and body mass will be measured using a balance beam scale (Detecto, Webb City, MO 
USA).  Whole blood samples will be placed in an IEC Centra-8R refrigerated centrifuge 
(International Equipment Company, Needham Heights, MA USA), and the resultant 
separated serum will be stored and frozen at -80°C (Thermo Electron Corporation, 
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Asheville, NC USA).  Serum CPII and C2C will be assessed using enzyme-linked 
immunosorbent assay (ELISA) kits (IBEX technologies, Montreal, Quebec, Canada).   
Procedures 
Session I 
Participants will report to the Sports Medicine Research Laboratory (SMRL) in 
Fetzer Hall on UNC Chapel Hill’s campus for testing. Prior to participation, each 
participant will read and sign an informed consent form (Appendix 1). If the participant 
has any questions about the procedures or the study in general, he/she will have the 
option to ask the researcher. After consent is obtained, the investigator will screen the 
participants to see if they meet inclusion/exclusion criteria.  If subjects meet the criteria, 
practice gait trials will be performed to obtain walking speed and familiarize the subject 
with the force plates. Subjects will walk forward along a 6m (~20ft) walkway containing 
two force plates at a comfortable, self-selected “normal” speed. The plates are 
staggered so that an entire stance phase for both limbs can be obtained in a single 
walking trial. At least 5 practice trials will be performed to determine the average 
preferred speed and ensure subjects can consistently strike the force plate mounted in 
the walkway without noticeably altering their gait (i.e. “aiming” for the force plate). Gait 
speed will be monitored via an infrared timing system. The next session will then be 
scheduled. 
Session II 
Subjects will return to the SMRL at UNC Chapel Hill at their scheduled time and 
complete the Tegner activity level scale (Appendix 2), in order for the investigator to 
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gain information about the participant’s physical activity. Each participant will then 
undergo a blood draw and gait trial described below.  
Blood Draw and Handling Procedures 
Participant will lie down quietly for 30 minutes prior to the blood draw.  The blood 
sample will be collected via vacutainer from the antecubital vein using a 21-gauge 
needle and immediately stored on ice.  The sample will be centrifuged at 4° C and 4000 
rpm for 10 minutes. Plasma will be separated from blood samples and pipetted equally 
into 4, 1.5 mL cryovials and stored at -80° C in a freezer until later analysis at the end of 
the study.  These procedures follow the guidelines of Hackney and Viru for working with 
biological specimens (Hackney & Viru, 2008).  Sera will be assessed for markers of 
collagen synthesis (CPII) and collagen degradation (C2C). 
Gait Biomechanics Assessment 
Subjects will perform the analysis with bare feet and tight spandex shorts 
provided by the laboratory.  Men will be shirtless while women will wear a sports bra or 
a tank top based on preference.  Subjects will walk forward along a 6m (~20ft) walkway 
containing two force plates at a comfortable, self-selected “fast” speed while 
biomechanical data are collected. The plates are staggered so that an entire stance 
phase for both limbs can be obtained in a single walking trial. Gait speed will be 
monitored via an infrared timing system to ensure each trial is within ±5% of the 
previously determined speed. Kinetic measurements will be taken with each trial. 
Subjects will perform 5 valid trials from which gait biomechanical variables will be 
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averaged for statistical analysis. Ground reaction forces will be sampled at 1,200 Hz.  
The stance phase will be defined as the interval from ground contact (vGRF> 20 N) to 
toe off (vGRF<20 N).  For data analysis, peak vGRFs will be extracted from the first 
50% of the stance phase of gait. The bodyweight of each participant will be converted 
into Newtons to normalize peak vGRF was normalized to bodyweight/ seconds.  
Statistical Analysis 
This study will employ a descriptive laboratory-based design.  It will examine 
associations between biomarkers of type II collagen turnover and mechanical loading at 
the knee joint in healthy subjects.  The null hypothesis is that there will be no 
association between any of the biomarkers and mechanical loading.  The research 
hypothesis is that there will be a moderate positive association between the different 
biological markers and kinetic markers.  
SPSS statistical software will be used to analyze data (version 19.0, Chicago, IL, 
USA).  Significance for all data will be set at α < 0.05. Shapiro-Wilk test will be used to 
assess normality (Ghasemi & Zahediasl, 2012). 
Correlation of variables within normal distribution will be associated using 
Pearson Product (r) Moment, while those that fall outside the normal distribution will be 
evaluated using Spearman (ρ) correlation.  Correlation strength will be described as 
small (0.1-0.29), medium (0.30-0.49), or large (0.50-1.0) based upon the criteria of 
Cohen (1998). 
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Covariates of age, height, mass, and sex will be checked for association with 
serum and kinetic biomarker outcomes using either Pearson Product (r) Moment or 
Spearman (ρ) rank order where appropriate.  Any covariates that are significantly 
associated with any biochemical or biomechanical markers will be accounted for using 
partial correlation analysis. 
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Chapter 4: Results 
 
  Due to the number of experimental sessions, stringency of the inclusion criteria, 
and length of the protocol, biomarker and kinetic outcome measures were collected on 
24 out of the 30 initially enrolled subjects. Of the six who did not complete the study, two 
subjects had preexisting lower extremity conditions unknown at the time of enrollment 
and were asked to withdraw from the study. One subject withdrew after enrollment but 
prior to data collection due to injury. One subject withdrew after enrollment but prior to 
data collection due to scheduling conflicts. Two subjects were unable to complete the 
biomechanics session due to time constraints.  
Subject Characteristics 
Eight male and sixteen female healthy subjects completed the study. These 
subjects met all inclusion criteria: healthy and between the ages of 18-35 years, 
physically active, no history of lower limb orthopedic injury or surgery, no current 
fractures or activity restrictions, and no current musculoskeletal conditions. Participant 
physical characteristics are reported in Table 1. 
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Table 1: Descriptive Data for Subjects 
 
 
 
 
Peak Vertical Ground Reaction Force 
Shapiro-Wilk test confirmed normal distribution of peak vGRF on the dominant 
limb (W=0.080; in this test W>0.05 is considered normal) and non-dominant limb 
(W=0.187). There was a significant difference between peak vGRF normalized to body 
weight (BW) between the dominant limb (1.08±0.08 BW) and non-dominant limb 
(1.09±0.07 BW; p = 0.048) using a Paired samples t-test. The average limb symmetry 
index (non-dominant/dominant) was 1.01±0.03 as shown in Table 2.  
Table 2. Kinetic Data (Normalized to BW) for Subjects  
Measure Mean±SD 
Peak vGRF dominant limb (BW) 1.08±0.08  
Peak vGRF non-dominant limb (BW) 1.09±0.07  
Limb Symmetry Index 1.01±0.03 
 
Type II Collagen Turnover 
CPII, a marker of type II collagen synthesis, was not normally distributed 
(W<0.001) with a mean value of 12538.9±58857.7 ng/mL. C2C, the type II collagen 
Measure Male (n=8) Female (n=16) n=24 
Age (yr) 21±2 20±1 20±2 
Height (cm) 177.4±6.5 165.4±6.5 169.4±8.6 
Body Mass (kg) 
BMI (kg/m2) 
 
76.8±8.2 
24.4±0.7 
62.8±10.7 
22.9±0.8 
67.5±11.8 
23.4±3.0 
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degradation marker, was normally distributed (W=0.565) with an average value of 
106.3±54.1 ng/mL. Due to the synthesis marker (CPII), the turnover ratio was also 
skewed (W<0.001) with an average value of 115.2±529.1.  All data is shown in Table 3. 
The mean intra-assay coefficient of variation of the CPII ELISA was 2.7%, and the mean 
coefficient of variation of the C2C ELISA was 18.1%.  
Table 3. Biomarker Data for Subjects 
Measure Mean±SD 
CPII (ng/mL) 12538.9±58857.7 
C2C (ng/mL) 106.3±54.1 
CPII:C2C 115.2±529.1 
 
Associations Between Cartilage Metabolism and Peak Vertical Ground Reaction 
Force 
No significant associations existed between the CPII:C2C ratio and peak vGRF 
(rho=0.185; p=0.386) using Spearman’s correlation analysis.  Additionally, no significant 
associations were found between individual CPII or C2C biomarkers and peak vGRF 
(rho=0.110, p=0.609; r= -0.115, p=0.592) using Spearman’s and Pearson correlation 
analysis, respectively. 
Post Hoc Analysis 
 
Due to non-normal distribution of the CPII:C2C ratio, as affected by outliers, 
several exploratory analyses were conducted in which data were transformed and, or 
outliers eliminated.  Due to the focus of this study, only associations between peak 
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vGRF and the biomarker ratio (CPII:C2C) were examined with correlation analysis.  
Outlier Removal 
Subject 3 was considered an outlier due to a CPII concentration of 288911.38 
ng/mL (i.e., greater than three standard deviations above the mean response; Howell, 
1998). After removal of this subject, CPII:C2C mean and standard deviation was 
lowered substantially, as shown below in Table 4. CPII was normally distributed 
(W=0.365) with an average value of 569.6±163.6 ng/mL. C2C was normally distributed 
(W=0.508) with an average of 106.0±55.3 ng/mL.  CPII:C2C ratio, however, was still not 
normally distributed (W=0.000) with an average value of 7.2±5.1. 
Table 4. Biomarker Data for Corrected Subjects 
Measure Mean±SD 
CPII (ng/mL) 569.6±163.6 
C2C (ng/mL) 106.0±55.3 
CPII:C2C 7.2±5.1 
  
With the outlier removed, there was no significant correlation between CPII:C2C 
and peak vGRF (rho=0.079, p=0.720) using Spearman’s analysis. 
Transformed Data 
All biomarkers were subsequently transformed to a base-10 log scale value, but 
the outlier value was not removed.  These data are shown below in Table 5.  Both CPII 
and C2C were not normally distributed (W=0.000, W=0.000), but CPII:C2C was 
normally distributed (W=0.240). 
	 	 	29	
Table 5. Transformed (Base-10 log) Biomarker Data 
 
 
 
 
 
There was a correlation between CPII:C2C and peak vGRF which trended 
towards significance (r=0.363, p=0.081) using Pearson product moment correlations.  
Associations with Physical Activity and CPII:C2C 
Further explorative analysis showed an association between physical activity 
(PA) level and the biomarker ratio. PA was assessed via Tegner scale (on a 1-10 
scale). The average Tegner scale for the raw data and the raw data with the outlier 
removed was 4.2±1.1, and neither were normally distributed (W=0.001, W=0.002).  
 Partial correlations analyses controlling for the Tegner scale was conducted 
within the three data sets (raw, outlier removed, transformed). There was a significant, 
moderate partial correlation between peak vGRF and CPII:C2C using raw data 
(r=0.428, p=0.042), no significant partial correlation once the outlier was removed (r=-
0.076, p=0.735), and a partial correlation trending toward significance using the 
transformed data (r=0.392, p=0.064). As noted, not all data was normally distributed, 
but a nonparametric partial correlation analysis does not exist, therefore the parametric 
partial correlation approach was utilized. These results are shown below in Table 6. 
 
Measure Mean±SD 
CPII (ng/mL) 2.8±0.6 
C2C (ng/mL) 2.0±0.3 
CPII:C2C 0.9±0.6 
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Table 6. Partial Correlations of Peak vGRF and CPII:C2C Controlled for PA 
Covariate Data Set r p Association 
Tegner Scale Raw data 0.428 0.042 Significant, moderate  
Outlier Removed -0.076 0.735 No association 
Transformed 0.392 0.064 Non-significant, weak 
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Chapter 6: Discussion 
The purpose of this study was to examine associations between biochemical 
markers of cartilage metabolism and peak vGRF in young, healthy individuals. The 
research hypothesis stated that increases in peak vGRF in the first 50% of stance 
phase of gait would associate with a decrease in synthesis-to-degradation biomarker 
ratio. To test this hypothesis, gait kinetics and resting serum samples were measured in 
24 young, healthy subjects.  
The primary finding of the study showed a small non-significant association 
between peak vGRF and CPII:C2C. It was noted previously that the data was not 
normally distributed due to an extremely high CPII value (i.e., single individual).  With 
the removal of this outlier, there was no correlation between peak vGRF and CPII:C2C. 
However, this data was still not normally distributed due to several moderately high 
CPII:C2C values that substantially skewed data but could not qualify as outliers (i.e. 
these values were ~2 standard deviations above the normal).  Additionally, due to the 
small sample size, removal of further subjects would lower statistical power 
considerably. Therefore, in order to preserve statistical power and normalize the data, 
CPII:C2C was transformed to a base-10 log scale value. When data was transformed, 
there was a moderate correlation trending toward significance between peak vGRF and 
CPII:C2C.   
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The association between peak vGRF and CPII:C2C does change based on the 
data set analyzed (raw data vs. removed outlier vs. transformed), and this wide range of 
CPII:C2C values may be due in part to the variability of the study population.  This study 
enrolled participants of widely varying PA levels, from individuals who strength trained 
very regularly to half-iron man athletes to individuals that merely met the required 
guidelines of 20 minutes of activity three times a week.  In an effort to control for this 
variance in PA level and its potential impact on outcomes, partial correlations were 
analyzed with Tegner activity level scale as a covariate. Although the Tegner scale does 
not take into account the type of activity performed and focuses more on competition 
level rather than amount of training, it is a common survey used to assess functionality 
after knee surgery and is transferable to a healthy population (Briggs et al. 2009). After 
controlling for PA with the Tegner activity level scale, there was a moderate and 
significant correlation between peak vGRF and CPII:C2C. However, this data also 
appears influenced by several very high CPII:C2C values of a few individuals within the 
data set. Once again, in an effort to maintain statistical power and normalize data, a 
partial correlation was conducted controlling for PA using the transformed base-10 log 
data on all data values.  Using the transformed data, there was a moderate correlation 
approaching significance between peak vGRF and CPII:C2C. 
 Although interpretation of this data will vary based on the reader’s opinion, this 
discussion will focus primarily on the positive association between peak vGRF and 
CPII:C2C in the transformed data. CPII:C2C is the ratio of type II collagen synthesis to 
degradation.  In previous studies it has been shown that this turnover shows changes in 
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early OA and can predict OA progression better than synthesis or degradation markers 
alone (Garnero et al., 2002; Cahue et al., 2007).  This study provides evidence that 
increased peak vGRF in the first 50% stance phase of gait may be associated with 
higher levels of type II collagen synthesis to degradation ratio. Increased PA activity 
levels may be associated with higher synthesis-to-degradation turnover of type II 
collagen as well. 
Association Between Joint Loading and Cartilage Turnover 
Although it is outside the scope of this study to determine the causation of peak 
vGRF and CPII:C2C within this cohort of healthy individuals, it is well researched that 
cyclic loading occurring during normal and healthy gait is a critical component of 
extracellular matrix metabolic activity.  Throughout the past several decades, studies 
have examined cyclic loading both in vitro and in vivo to investigate metabolic response 
in articular cartilage (Ikenoue et al., 2003; Saadat et al., 2006; Steinmeyer and Knue, 
1997).  
Many in vitro studies have demonstrated an increase in cartilage synthesis as a 
result of cyclic loading.  In these studies, cyclic loading was achieved using mechanical 
apparatuses that applied air or hydro-powered stresses at a range of frequencies. In 
mature bovine articular cartilage explants, proteoglycan biosynthesis within the nutrient 
media surrounding the cartilage increased as the cyclic load applied increased from 0.1 
megapascal (MPa) to 5.0 MPa (Steinmeyer and Knue, 1997). It was hypothesized that 
increasing the overall deformation of the cartilage explant contributed to the additional 
proteoglycan release. Additionally, this study provided evidence that proteoglycan 
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synthesis within the matrix may be more dependent on frequency and duration of the 
load rather than the total magnitude of the load. Reducing frequency from 0.5 Hz to 
0.001 Hz resulted in decreased inhibition of proteoglycan biosynthesis, and reduced 
proteoglycan release accompanied an increase in loading duration (Steinmeyer and 
Knue, 1997).  Type II collagen was not measured during this study, which was most 
likely due to the much slower turnover rate of collagen compared to proteoglycan (Bank 
et al., 1998).  This increase in proteoglycan biosynthesis as well as type II collagen 
synthesis was found in a similar study examining human articular cartilage explants 
(Ikenoue et al., 2003). By applying intermittent hydrostatic pressure four hours a day for 
four days, proteoglycan signal levels increased as the amount of load increased from 
one to ten MPa.  At higher loads of five and ten MPa, type II collagen signal levels were 
upregulated as well (Ikenoue et al., 2003).  This study suggests that higher loading, as 
long as the loading is not abnormal or injurious in nature, may contribute to increased 
synthesis of cartilage macromolecules.  
 Loading studies performed on animals in vivo have also examined the 
association between proteoglycan biosynthesis and cyclic joint loading. In a rabbit 
model, cyclic joint loading was applied between one and two MPa for a cumulative 80 
hours. There was a statistically significant increase in proteoglycan content in the 
loaded limb compared to the control limb for all six rabbits (Saadat et al., 2006).   This 
study concluded that an increase in proteoglycan synthesis was stimulated via signal 
transduction by increases in hydrostatic pressure. These studies suggest that in healthy 
and normal cartilage, an increase in load may contribute to an increase in cartilage 
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synthesis, thereby increasing the synthesis-to-degradation ratio.  
 Although studies examining associations of loading and cartilage metabolism in 
young, healthy human subjects are limited, studies have examined similar parameters in 
both ACL reconstruction (ACLr) subjects and subjects with KOA. In one cohort of ACLr 
subjects, higher peak vGRF in the injured limb was moderately associated with 
CPII:C2C (Pietrosimone et al., 2016).  It was hypothesized that higher amounts of 
cartilage synthesis were necessary to mitigate the peak vGRF during gait, and it was 
noted there were no significant differences in peak vGRF between limbs. Because 
biomarkers were collected from serum rather than synovial fluid, CPII:C2C ratios are 
representative of all physiological type II collagen rather than CPII:C2C specific to knee 
articular cartilage.  It is possible that in this ACLr sample higher peak vGRF resulted in 
higher CPII:C2C ratios in both the injured and uninjured limb.  It has been shown that 
subjects with KOA generally have a lower GRF than healthy controls, although this may 
be a result of decreased walking speed (Zeni and Higginson, 2009). Additionally, 
several studies have shown that a decrease in collagen synthesis compared to 
degradation is a good predictor of OA progression (Cahue et al., 2007; Garnero et al., 
2002).  Overall, these findings tentatively suggest that an increase in joint loading may 
associate with an increased stimulus for collagen synthesis rather than degradation in 
healthy human cartilage. 
Physical Activity and Biomarkers of Cartilage Metabolism 
An exploratory analysis finding of the present study was that PA was a covariate 
of CPII:C2C and peak vGRF. Several subjects in the study regularly participated in 
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running or sports that involved running, and it was observed that these subjects tended 
to have higher ratios of CPII:C2C. Previous research has shown benefits of load bearing 
activities (i.e., walking and running) including improved blood circulation to tissue fluid 
and increased lubrication of joints from synovial fluid (Renstrom, 1991; Simkin et al., 
1990). While most researchers agree that immobilization or under-loading of a joint 
tends to weaken cartilage (Foley et al., 2007) and excessive loading can lead to 
cartilage loss (Roos and Dahlberg, 2005), there seems to be mixed opinions on what 
constitutes excessive loading.  
In one study, a total of 297 healthy adults between the ages of 50-79 underwent 
MRI examinations and answered questions about their regular PA (Racunica et al., 
2007).  Results showed that increases in tibial cartilage volume associated with higher 
frequency and duration of vigorous PA.  However, many other studies show that 
markers of cartilage degradation increase both after an acute running session and at 
rest in chronic runners (O’Kane et al., 2006). It should be noted that in O’Kane’s study, 
markers of cartilage synthesis and cartilage turnover were not presented in the results.  
It may be that subjects within the present study all participated in a healthy amount of 
weight bearing activity, thus stimulating more collagen synthesis than degradation.  The 
findings from the present study agree with previous research that additional loading can 
contribute to an increase of type II collagen synthesis relative to degradation. 
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Limitations 
While this current study provided new insight of loading and cartilage metabolism 
in a healthy population, there were limitations to acknowledge. The current study might 
be underpowered with only 24 subjects completing all aspects of the experimental 
sessions (hence the low correlation coefficients and significance level found in some 
analysis); however, this low level of association may be what exists physiologically.  The 
subjects, while healthy and similar in age, had wide variation in the amount and type of 
PA each subject participated in. In the future, it may be more useful to limit the study to 
subjects that participate in a certain amount of weight-bearing activities. This study did 
not control for amount of PA completed the day of the session. Although participants 
were asked to refrain from exercising the day of the study and sat for 30 minutes prior to 
data collection, participants walked through campus to get to the testing laboratory. 
Additionally, some subjects reported to the laboratory first thing in the morning, some in 
the afternoon, and others at night. This most likely influenced CPII:C2C ratio 
considering many subjects walked to and from numerous classes the day of their testing 
session.  
 Measurements of CPII and C2C were taken from serum rather than synovial 
fluid. Since CPII and C2C biomarkers are representative of all physiological type II 
collagen, this means that the CPII:C2C ratio is not specific to the knee.  It is possible 
that any injury or cartilage abnormality in another joint could affect turnover ratio.  Serum 
was taken rather than synovial fluid due to the impracticality of taking synovial fluid both 
in the current study, future studies, and in a clinical application.   
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 Another limitation may have been that this study focused on degradation only in 
articular cartilage rather than other parts of the knee. The literature suggests that 
changes to other surrounding tissues such as synovial fluid (Benito et al., 2005) and 
bone (Ishijima et al., 2011) may accompany or occur prior to cartilage breakdown.    
 PA was quantified through the Tegner activity level scale. This scale is a 1-10 
rating based on the type of PA in which the subject participates. The Tenger scale 
emphasizes the level of competition rather than the amount of PA completed, which is 
not always relevant in a university setting. Many subjects in various studies may 
maintain a high training load despite not participating at a varsity or competitive level. 
Additionally, no distinction is made for the type of PA. It is important to recognize that 
loading is very different for a rower, swimmer, or runner despite the competition level 
(O’Kane et al., 2006). Future studies assessing the association between PA and 
cartilage biomarkers may benefit from a different survey to assess PA level.   
 However, this study is practical because there were few barriers to collecting 
data from subjects, and it is very reflective of the real world. Subjects did not have to 
limit walking or light PA activity prior to coming in, and the protocol was not very time or 
activity intensive. Gait trials generally took 30 minutes in total, and the blood-draw, 
including a 30-minute rest, took about 45 minutes. This study could be easily replicated 
in any laboratory with force plates and blood-draw materials.   
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Conclusion 
The data presented in the results of this study can be interpreted several different 
ways.  Analyzing the raw biomarker data, there was no correlation between peak vGRF 
and CPII:C2C. However, by using a base-10 log transformation, the data was 
normalized and a correlation existed between peak vGRF and the transformed 
CPII:C2C.  The discussion of this study focused on the transformed biomarker data in 
order to analyze a normally distributed data set.  Using the transformed biomarker data, 
it was found that the ratio of serum markers of type II collagen synthesis to degradation 
is associated with peak vGRF in the first 50% stance phase of gait in healthy, young 
adults.  The positive association between these markers in the present study agrees 
with data found in previous research (Ikenoue et al., 2003; Saadat et al., 2006).  This 
data contrasts with the research hypothesis, which stated that peak vGRF and 
CPII:C2C would be negatively associated with each other.  This hypothesis was driven 
by previous analysis on aberrant loading mechanics in subjects with idiopathic KOA 
(Torzilli et al., 1999; Sun, 2010).  It is now realized that this association does not carry 
over to a non-clinical population.  This study provides evidence that an increase in the 
magnitude of load during healthy normal gait may stimulate more type II collagen 
synthesis with respect to degradation.  
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APPENDIX 1: IRB APPROVED CONSENT FORM 
University of North Carolina at Chapel Hill 
Consent to Participate in a Research Study 
Adult Participants 
 
Consent Form Version Date: ______________ 
IRB Study # 15-1003 
Title of Study: Disability, Biomechanical, Biochemical and Diagnostic Ultrasound Outcomes 
Following Anterior Cruciate Ligament Reconstruction: A Case-Control Study 
Principal Investigator: Brian Pietrosimone 
Principal Investigator Department: Exercise and Sport Science 
Principal Investigator Phone number: 962-3617 
Principal Investigator Email Address: pietrosi@email.unc.edu  
Co-Investigators: Troy Blackburn, Anthony Hackney, Yvonne Golightly, Darin Padua 
 
Study Contact Telephone Number: 843-2014 
Study Contact Email: harkman@live.unc.edu 
 
_________________________________________________________________ 
 
What are some general things you should know about research studies? 
You are being asked to take part in a research study.  To join the study is voluntary. 
You may refuse to join, or you may withdraw your consent to be in the study, for any reason, 
without penalty. 
 
Research studies are designed to obtain new knowledge. This new information may help people 
in the future.   You may not receive any direct benefit from being in the research study. There 
also may be risks to being in research studies. Deciding not to be in the study or leaving the 
study before it is done will not affect your relationship with the researcher, your health care 
provider, or the University of North Carolina-Chapel Hill. If you are a patient with an illness, 
you do not have to be in the research study in order to receive health care. 
 
Details about this study are discussed below.  It is important that you understand this information 
so that you can make an informed choice about being in this research study.  
 
You will be given a copy of this consent form.  You should ask the researchers named above, or 
staff members who may assist them, any questions you have about this study at any time. 
 
What is the purpose of this study? 
The purpose of this research study is to determine how different types of physical activities (i.e. 
walking/running/jumping) affect indicators of knee cartilage health in individuals following ACL 
injury and reconstruction compared to healthy control participants.  
You are being asked to be in the study because you have undergone ACL reconstruction surgery 
OR you are a healthy, physically active person between the ages of 18-35 years. 
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Are there any reasons you should not be in this study? 
 
If you have undergone ACL reconstruction surgery, you should not be in this study if you: 
1) Are not between the ages of 18-35 
2) Have injured the ACL in BOTH of your legs 
3) Have re-injured your ACL or required a second/revision ACL surgery following your 
initial ACL injury 
4) Received your ACL reconstruction surgery less than 6 months ago 
5) Have injured either of your legs within the last 6 months 
6) Have not been cleared by your physician to return to physical activity 
7) Do not currently participate in at least 20 minutes of physical activity 3x per week 
8) Are currently pregnant  
If you are a healthy individual who has not undergone ACL reconstruction surgery, you 
should not be in this study if you 
1) Have a history of lower extremity surgery or ligamentous knee injury 
2) Have chronic ankle instability or balance disorders 
3) Are not physically active 
4) Have concussion or head injury in the past 6 months 
5) Have a history of cardiac condition or stroke 
6) Are currently pregnant 
How many people will take part in this study? 
There will be approximately 60 people in this research study. Specifically, there will be 30 
participants following ACLR and 30 Healthy participants. 
 
How long will your part in this study last? 
If you agree to participate, you will be asked to report to the Sports Medicine Research 
Laboratory in Fetzer Hall on the UNC-Chapel Hill campus for 3 testing sessions separated 
by 1 week.  Each testing session will last approximately 1.5 hours.  
 
What will happen if you take part in the study? 
 
Session 1 
Disability Outcomes 
When you arrive to the laboratory, you will complete several electronic forms that will 
evaluate your knee function and physical activity level. 
 
Blood Draw 
We will then take a small (~10mL) blood sample that will be used to help determine the 
health of your knee cartilage.  You will be sitting in a chair while someone trained in 
phlebotomy (blood drawing) takes the sample.  We will keep these samples for up to 4 
years following the end of the study. 
 
Biomechanics Outcomes 
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You will perform a 5 minute “warm up” on a stationary bicycle.  We will then place 
sensors on your legs, pelvis, and trunk that will allow us to measure movements of your 
joints, as well as sensors on the front and back of your legs to measure muscle activity.  The 
areas where we will place some of these sensors will be shaved, lightly abraded, and cleaned 
with alcohol to improve adhesion to the skin and signal quality.   
 
1) Gait Biomechanics Assessment – you will be asked to walk forward along a 20 foot 
walkway at a comfortable, self-selected “fast” speed while movements of your legs 
are collected.  You will be asked to walk over a device that will measure how hard 
you are stepping on the ground.  You will perform at least 5 practice trials to ensure 
that you are comfortable walking with the sensors.  You will then perform 5 trials 
that will be recorded 
 
2) Landing Biomechanics Assessment – You will be asked to stand on top of a 12 inch 
box that is placed half of your height away from the devices (force plates) in the 
ground that measure the force you apply to the ground during landing.  During 
each trial, you will be asked to jump off the box using both legs, land with one foot 
on each force plate, and immediately jump vertically as high as you can.  You will be 
allowed to practice this landing as many as 3 times to ensure that you are 
comfortable with the task.  You will then perform 5 trials that will be recorded. 
 
3) Squatting Assessment – You will be asked to stand with your feet shoulder-width apart 
and your arms raised over your head. You will then descend into a double-leg squat as far 
as you can comfortably go, and then return to the starting position while motion patterns 
of your legs are measured. You will perform 5 trials of this task.  
 
4) Voluntary Activation - You will be asked to perform maximal contractions of the 
quadriceps muscle on the front of your thigh.  You will be seated and asked to kick out 
your leg against a device that measures how much force you can produce.  During the 
contraction, a very brief (less than 1/1,000th of a second) pulse of electricity will be sent 
to your quadriceps muscle.  This pulse of electricity will allow us to measure muscle 
function and is similar to a strong “carpet shock”.  You will complete a warm up that will 
help you become comfortable and familiar with the electrical stimulus, after which 2 
trials will be recorded.  The stimulator used in this study is not FDA approved. 
 
5) 40-Meter Walk Test – You will be asked to complete 5 trials where you will walk 40-
meters.  You will be timed to see how fast that you can complete the 40-meter walk. 
 
Ultrasound Outcomes 
You will then lay on a table with your knee bent.  We will use an ultrasound unit to take a 
picture of the inside of your knee to measure the size of your joint cartilage. 
 
Loading Condition 
You will then be randomized into one of three loading conditions (i.e. running, walking, 
sitting).  You will complete 30 minutes of the loading condition then we will re-measure the 
size of your knee cartilage. 
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Session 2  
Disability Outcomes - Same as above 
 
Blood Draw – Same as above 
 
Biomechanics Outcomes – Same as above 
 
Ultrasound Outcomes – Same as above 
 
Loading Condition – You will then complete one of the other loading conditions for 30 
minutes.  We will then re-measure your knee cartilage size following this loading condition. 
 
Session 3 
Ultrasound Outcomes - Same as above 
 
Loading Condition – You will then complete the last of the three loading condition for 30 
minutes.  We will then re-measure your knee cartilage size following this loading condition.  
 
What are the possible benefits from being in this study? 
Research is designed to benefit society by gaining new knowledge.  You will not benefit 
personally from being in this research study.  However, identifying early function, 
biomechanical, and cartilage healthy changes following ACL reconstruction will be important in 
preventing the future development of osteoarthritis within this patient population. 
  
What are the possible risks or discomforts involved from being in this study? 
The quadriceps contractions during the voluntary activation testing may infrequently result in 
muscle soreness or, in extremely rare cases, muscle injury. The electrical stimulation used during 
the Muscle Function Assessment, though extremely brief (less than 1/1000th of a second), may 
cause discomfort – but not pain – during testing.  
Similarly, the physical tasks you will perform (Landing, Squatting, and Walking) carry the 
extremely rare potential for musculoskeletal injury.  However, because you are physically active, 
these risks are minimal and are not different from the risks you experience with normal physical 
activity/exercise.  Additionally, there is a very minimal risk that preparing the skin (i.e. shaving, 
lightly abrading, and cleaning) for sensor placement will result in discomfort. 
Risks associated with blood draws include infection, hematoma or bruising of the area around 
the needle insertion, and dizziness/fainting.  A certified phlebotomist will perform all blood 
draws.  First aid procedures and universal precautions will be followed during blood draws and 
handling of blood samples.  To minimize the risk of infection, cleaning of the puncture area and 
sterile equipment will be used.  Proper needle gauge and firm pressure applied to the puncture 
following the blood draw will help minimize risk of bruising.  Following the blood draw, to 
minimize the risk of fainting you will be asked to move from a lying to sitting and eventually to 
standing slowly. Research technicians are first aid, CPR and AED certified.  All blood draws will 
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be conducted by research assistants trained in phlebotomy under the supervision of a nationally 
certified phlebotomist.  
 
There may be uncommon or previously unknown risks. You should report any problems to the 
researchers. 
 
What if we learn about new findings or information during the study?  
You will be given any new information gained during the course of the study that might affect 
your willingness to continue your participation.  
 
How will information about you be protected? 
Any information obtained in connection with this research study that can be linked to you will 
remain confidential. You will be identified only by a subject identification number.  A code list 
that associates your name and information with a specific subject identification number will be 
kept under key-card access on a password-protected computer in the Neuromuscular Research 
Laboratory. Only the research team will have access to this information. 
 
Participants will not be identified in any report or publication about this study. Although every 
effort will be made to keep research records private, there may be times when federal or state law 
requires the disclosure of such records, including personal information.  This is very unlikely, 
but if disclosure is ever required, UNC-Chapel Hill will take steps allowable by law to protect 
the privacy of personal information.  In some cases, your information in this research study could 
be reviewed by representatives of the University, research sponsors, or government agencies (for 
example, the FDA) for purposes such as quality control or safety. 
 
What will happen if you are injured by this research? 
All research involves a chance that something bad might happen to you.  This may include the 
risk of personal injury. In spite of all safety measures, you might develop a reaction or injury 
from being in this study. If such problems occur, the researchers will help you get medical care, 
but any costs for the medical care will be billed to you and/or your insurance company. The 
UNC-Chapel Hill has not set aside funds to pay you for any such reactions or injuries, or for the 
related medical care. You do not give up any of your legal rights by signing this form. 
 
What if you want to stop before your part in the study is complete? 
You can withdraw from this study at any time, without penalty.  The investigators also have the 
right to stop your participation at any time. This could be because you have had an unexpected 
reaction, or have failed to follow instructions, or because the entire study has been stopped. 
 
Will you receive anything for being in this study? 
You will not receive anything for being in this study 
 
Will it cost you anything to be in this study? 
It will not cost you anything to be in this study.  
 
What if you have questions about this study? 
You have the right to ask, and have answered, any questions you may have about this research. If 
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you have questions about the study (including payments), complaints, concerns, or if a research-
related injury occurs, you should contact the researchers listed on the first page of this form. 
 
What if you have questions about your rights as a research participant? 
All research on human volunteers is reviewed by a committee that works to protect your rights 
and welfare.  If you have questions or concerns about your rights as a research subject, or if you 
would like to obtain information or offer input, you may contact the Institutional Review Board 
at 919-966-3113 or by email to IRB_subjects@unc.edu. 
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Participant’s Agreement: 
 
I have read the information provided above.  I have asked all the questions I have at this time.  I voluntarily agree to 
participate in this research study. 
  
 
______________________________________________________ 
Signature of Research Participant 
 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Research Participant 
  
 
______________________________________________________ 
Signature of Research Team Member Obtaining Consent 
 
____________________ 
Date 
 
______________________________________________________ 
Printed Name of Research Team Member Obtaining Consent 
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APPENDIX 2: IRB APPROVED STORED SPECIMENS CONSENT FORM 
 
University of North Carolina at Chapel Hill 
Consent for Storing Biological Specimens With Identifying Information 
______________________________________________________________________ 
 
Consent Form Version Date: ______________ 
IRB Study # 15-1003 
Title of Study: Disability, Biomechanical, Biochemical and Ultrasound Outcomes 
Following Anterior Cruciate Ligament Reconstruction: A Case-Control Study 
Principal Investigator: Brian Pietrosimone 
Principal Investigator Department: Exercise and Sport Science 
Principal Investigator Phone number: 962-3617 
Principal Investigator Email Address: pietrosi@email.unc.edu  
Co-Investigators: Darin Padua, Troy Blackburn, Anthony Hackney, Yvonne Golightly, 
Jeffrey Spang 
 
Study Contact Telephone Number: 843-2014 
Study Contact Email: harkman@live.unc.edu 
______________________________________________________________________ 
 
What are some general things you should know about research? 
Research is designed to gain scientific information that may help other people in the 
future. You may not receive any direct benefit from participating. There also may be 
risks. 
 
You may refuse to take part in research. If you are a patient with an illness, you do not 
have to be in research in order to receive treatment. 
 
Details are discussed below. It is important that you understand this information so that 
you can make an informed choice. You will be given a copy of this consent form. You 
should ask the researchers named above, or staff members who may assist them, any 
questions you have about this study at any time. 
 
What is the purpose of this specimen repository or “biobank?” 
Research with blood, tissue or body fluids (specimens) can help researchers 
understand how the human body works. Research can also answer other questions by 
using specimens. Researchers may develop new tests to find diseases, or new ways to 
treat diseases. In the future, research may help to develop new products, such as 
drugs. Specimens are commonly used for genetic research. Sometimes researchers 
collect and store many specimens together and use them for different kinds of research, 
or share them with other scientists; this is called a specimen repository or “biobank.” 
 
The purpose of this particular repository or biobank is to be able to evaluate your serum 
in the future for makers that may indicate the early development of knee arthritis. New 
markers are discovered and/or become available to test every year, therefore we plan to 
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store some of the serum found in your blood in a freezer. If a new marker of interest 
may provide further information regarding the development of knee arthritis we may test 
the serum that we have stored.  We will not perform any genetic research with your 
serum in the future.  
 
How will the specimens be collected? 
Blood will be collected from a vein the front of your elbow using a needle by a trained 
investigator. The blood will be stored in small tubes after collection. By agreeing to 
have your specimens stored, you will allow your medical facts, specimens and 
results from your participation in the UNC ACL study, but not your name, to be 
used in future studies. 
 
What will happen to the specimens? 
If you agree, after collecting your blood, we will store your samples for future testing of 
biomarkers that might partly cause osteoarthritis related to injuries of the joint.  The 
specimens will be stored with a number and not your name for an indefinite period of 
time. We will be able to match a specimen to an individual through use of a code that 
will be separate from the storage place of the samples.  The specimen codes will be 
stored on a password protected computer in the Neuromuscular Research Laboratory 
that is only accessible by the study personnel. We will keep your identity unknown to 
any other researchers and we will keep your records private to the extent allowed by 
law.   
 
We may use the blood samples for scientific research or teaching purposes.  We may 
also share the biomarkers with other researchers who work with us.  Dr. Pietrosimone 
will carefully review study proposals from other researchers interested in working with 
us and all studies will be submitted to the Institutional Review Board for approval. Some 
of the blood or other specimens you give in this study may be sent to pharmaceutical or 
other commercial companies for future studies. 
 
Your samples may be used in our research to help other researchers invent or find 
something new.  The aim is to use the finding and inventions to develop new products 
that may improve public health.  At times, such findings or inventions may have a value 
if they are made or sold.  The government, the university, our research team or partners 
may get a patent on these.  They may also license these.  You would not share in any 
money or other things that the government, the university, our research team or 
partners might get for what someone may invent or find using your study samples.  We 
have no reason to believe your samples will be used to invent or find something new, 
but we want you to know what will happen in case it does. 
 
The specimens will be stored in the Department of Exercise and Sport Science, or 
another site.  Dr. Brian Pietrosimone and special project staff members will have access 
to the specimens and the code, which links the specimen to you.  These samples will be 
stored with a number not your name for at least 20 years or until they are used up. 
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What are the possible benefits to you? 
Benefits to you are unlikely. Studies that use specimens from this repository may 
provide additional information that will be helpful in understanding the biochemical 
changes following ACL injury 
 
What are the possible risks or discomforts involved with the use of your 
specimens? 
There is a risk of breach of confidentiality.  
 
Will there be any cost to you for storage of the specimens? 
There will be no cost to you for the storage and use of the specimens for research 
purposes. 
 
Will you receive anything for the use of your specimens? 
You will not receive anything for the storage of your specimens in this study.  
 
Who owns the specimens? 
Any blood, body fluids, or tissue specimens obtained for this purpose become the 
exclusive property of the University of North Carolina at Chapel Hill. This organization 
may retain, preserve or dispose of these specimens and may use these specimens for 
research that may result in commercial applications. There are no plans to compensate 
you for any future commercial use of these specimens. Dr. Brian Pietrosimone, as the 
Principal Investigator of the “Disability, Biomechanical, Biochemical and Diagnostic 
Ultrasound Outcomes Following Anterior Cruciate Ligament Reconstruction: A Case-
Control Study”, study, is the custodian of any blood specimens obtained for the purpose 
of this study or any future studies in collaboration with other researchers, 
pharmaceutical or other commercial companies. 
 
How will information about you be protected? 
No one will be identified in any report or publication about these future studies.  
Although every effort will be made to keep research records private, there may be times 
when federal or state law requires the disclosure of such records, including personal 
information. This is very unlikely, but if disclosure is ever required, UNC-Chapel Hill will 
take steps allowable by law to protect the privacy of personal information.  In some 
cases, your information in this research study could be reviewed by representatives of 
the University, research sponsors, or government agencies for purposes such as quality 
control or safety. 
 
The specimens may be shared with researchers at this or other institutions. Research 
studies may be done at many places at the same time. Your personal identifying 
information will not be sent to other researchers. 
 
You will not be identified in any report or publication about research using your 
specimens. Although every effort will be made to keep research records private, there 
may be times when federal or state law requires the disclosure of such records, 
including personal information. This is very unlikely, but if disclosure is ever required, 
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UNC-Chapel Hill will take steps allowable by law to protect the privacy of personal 
information. In some cases, your information in this research could be reviewed by 
representatives of the University, research sponsors, or government agencies for 
purposes such as quality control or safety. 
 
Will researchers seek approval from you to do future studies involving the 
specimens? 
By signing this consent form, you are giving your permission for researchers to use your 
specimens as described above. Current and future research is overseen by a 
committee called the Institutional Review Board (IRB). The role of the IRB is to protect 
the rights and welfare of research participants. In some cases, the IRB may require that 
you be re-contacted and asked for your consent to use your specimens in a specific 
research study. You have the right, at that future time, not to participate in any research 
study for which your consent is sought. Refusal to participate will not affect your medical 
care or result in loss of benefits to which you are entitled. 
 
Will you receive results from research involving your specimens? 
Most research with your specimens is not expected to yield new information that would 
be meaningful to share with you personally. There are no plans to re-contact you or 
other subjects with information about research results. 
 
Can you withdraw the specimens from the research repository? 
If you decide that you no longer wish for the specimens to be stored, you should contact 
the researchers on the front page of this form. It is best to make your request in writing. 
 
Any analysis in progress at the time of your request or already performed prior to your 
request being received by the researcher will continue to be used as part of the 
research study. Once the researchers have been notified, your remaining specimens 
would be destroyed. If you do not make such a request, the specimens may be stored 
forever. The researchers may choose to destroy the specimens at any time. 
 
What will happen if you are injured by this research? 
All research involves a chance that something bad might happen to you. This may 
include the risk of personal injury. In spite of all safety measures, you might develop a 
reaction or injury from having your specimen collected. If such problems occur, the 
researchers will help you get medical care, but any costs for the medical care will be 
billed to you and/or your insurance company. The University of North Carolina at Chapel 
Hill has not set aside funds to pay you for any such reactions or injuries, or for the 
related medical care. However, by signing this form, you do not give up any of your 
legal rights. 
 
Who is sponsoring this research? 
This research is funded by the Department of Exercise and Sport Science at the 
University of North Carolina. This means that the research team is being paid by the 
sponsor for doing the study.  The researchers do not, however, have a direct financial 
interest with the sponsor or in the final results of the study. When appropriate, the last 
	 	 	51	
sentence should be modified to disclose the nature of any potential conflicts of interest 
relating to this study, financial or otherwise. 
 
What if you have questions about this research? 
You have the right to ask, and have answered, any questions you may have about this 
research. If you have questions, you should contact the researchers listed on the first 
page of this form. 
 
What if you have questions about your rights as a research subject? 
All research on human volunteers is reviewed by a committee that works to protect your 
rights and welfare.  If you have questions or concerns about your rights as a research 
subject you may contact, anonymously if you wish, the Institutional Review Board at 
919-966-3113 or by e-mail to IRB_ subjects@unc.edu. 
  
 
 
Title of Study: Project Title: Disability, Biomechanical, Biochemical and Diagnostic 
Ultrasound Outcomes Following Anterior Cruciate Ligament Reconstruction: A Case-
Control Study 
 
Principal Investigator: Brian Pietrosimone 
 
Subject’s Agreement  
I have read the information provided above.  I have asked all the questions I have at this 
time.  I voluntarily agree to participate.  I agree to my specimen(s) being stored with the 
identifying code(s). 
 
__________________________________________________ 
Signature of Research Subject 
 
___________________ 
Date 
 
__________________________________________________ 
Printed Name of Research Subject 
  
    
 
  
____________________________________________________   
Signature of Research Team Member Obtaining Consent 
 
________________ 
Date 
 
__________________________________________________ 
Printed Name of Research Team Member Obtaining Consent  
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APPENDIX 3: TEGNER ACTIVITY LEVEL SCALE
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